Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose intravenous methylprednisolone for complicated or fulminant acute myocarditis
2021-000938-34Phase 3Active
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in acute myocarditis comparing Pulse intravenous methylprednisolone plus standard therapy with Placebo plus standard therapy (2 arms). Primary endpoint: Primary composite endpoint. Started Jun 2021; status: active.
02
Drugs
methylprednisolone
03
Conditions
acute myocarditis
Beyond the preview
Go deeper on 2021-000938-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000938-34.